CSYS yields 200000000.00% · PFE yields 6.20%● Live data
📍 CSYS pulled ahead of the other in Year 1
Combined, CSYS + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CSYS + PFE for your $10,000?
ClearStory Systems, Inc. develops digital asset management (DAM) and enterprise content management software solutions. The company offers Radiant Enterprise Media Server (RADIANT EMS), a J2EE platform for document and media solutions; ActiveMedia, an enterprise DAM application that is built on Radiant EMS platform, which offers a secure central repository where rich media files, such as images, documents, video, animation, and voice formats of media and brand assets are organized and stored; Radiant Business Document Server, a system for document capture, archiving, and online presentment; and Radiant Mailmanager, an email archiving solution that provides lifecycle, compliance, and storage management for the corporate email knowledge. It also provides standards based technology solution, a platform for integrating media and business documents into various business environments, such as marketing and finance departments, call centers, channel partner portals, compliance initiatives, and marketing extranets. The company serves media and entertainment, pharmaceutical, consumer packaged goods, financial services, and healthcare industries. ClearStory Systems, Inc. was formerly known as INSCI Corp. and changed its name to ClearStory Systems, Inc. in December 2001. The company was founded in 1989. The company is based in Westborough, Massachusetts. ClearStory Systems, Inc. operates as a subsidiary of Piksel, Inc.
Full CSYS Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.